Ann Dermatol.  1995 Apr;7(2):121-126. 10.5021/ad.1995.7.2.121.

Immunohistochemical Study of Fibrohistiocytic Tumors of the Skin

Abstract

BACKGROUND
Histologic distinction between various fibrohistiocytic tumors of the skin may sometimes be difficult. Recently, several immunohistochemical markers of "histiocytes and "facultative fibroblasts" have been introduced and used for the study of some fibrohistiocytic tumors of the skin.
OBJECTIVE
The purpose of this study is to determine whether immunostatining with MAC 387, antibodies to S-100 protein, factor Xllla(FXllla) and CD 34 allows distinction between various fibrohistiocytic tumors of the skin in formalin-fixed, paraffin-embedded specimens.
METHODS
Paraffin-embedded specimens of dermatofibroma, keloid, hypertrophic scar, dermatofibrosarcoma protuberans(DFSP), neurofibroma, and juvenlie xanthogranuloma were investigated with MAC 387, antibodies to S-100 protein, CD 34 and FXllla using avidin-biotin -peroxidase complex method.
RESULTS
In all fibrous dermatofibromas (n=26), 20-90% of constituent cells were positive for FXllla. Focal or diffuse CD 34 reactivity was present in DFSP (n=2). Weak reactivity for CD 34 and consistent labeling for S-100 protein were found in neurofibromas (n=5). Tumor cells showed negative for FXllla, CD 34 and S-100 protein in keloids (n=2), hypertrophic scars (n=6), and juvenile xanthogranulomas (n=5). MAC 387 did not label tumor cells of the fibrobistiocytic tumors we have studied.
CONCLUSION
Immunostaining of paraffin-embedded specimens with antibodies to S-100 protein, FXllla and CD 34 may be useful in the differential diagnoses of fibrohistiocytic tumors of the skin.

Keyword

CD34 Factor XIIIa; Fibrohistiocytic tumors of the skin; MAC387; S-100 protein

MeSH Terms

Antibodies
Cicatrix, Hypertrophic
Dermatofibrosarcoma
Diagnosis, Differential
Histiocytoma, Benign Fibrous
Keloid
Methods
Neurofibroma
S100 Proteins
Skin*
Xanthogranuloma, Juvenile
Antibodies
S100 Proteins
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr